London – A study by researchers at the University of Oxford in England suggests that the risk of developing dangerous and rare blood clots in the brain is much higher in those who catch coronavirus that in those receiving the AstraZeneca vaccine or vaccines manufactured by Pfizer and Moderna in the US Research shows that the number of people who experience clots after receiving vaccines produced by US pharmaceutical giants seems very similar to the number of rare vaccines condition after a shot of the drug AstraZeneca, which was developed in conjunction with the Oxford Vaccine Institute.
A key finding of the research, revealed Thursday as a “preprinted” study that has not yet been reviewed by other scientists, was that the risk of a blood clot in the brain was about 95 times higher for people taking COVID. – 19 than in the general population.
This is another serious health threat associated with the disease and scientists expected it to increase confidence in all major vaccines currently available in the Western world, as their research suggests that the drugs pose a significantly lower threat of clotting. to the disease they have. He has been shown to defend.
Analysis of real-world data collected by the global health research network TriNetX and European agencies included information on hundreds of thousands of people who captured or received COVID-19 AstraZeneca, Pfizer or Modern shots. Most of the data on mRNA-type vaccines, which are U.S. drugs, came from the U.S., while data on AstraZeneca traits came largely from Europe’s mass vaccination programs.
The data showed that approximately 4 out of every 1 million people who receive vaccines made in the United States experience cerebral venous thrombosis (CVD) or blood clots in the brain. With the AstraZeneca vaccine, it works differently and is similar to the Johnson & Johnson fired, research showed an incidence rate of approximately 5 per million.
This equates to a 10 times higher risk of TVC for people who catch the coronavirus than for those who receive the Pfizer or Moderna vaccine and 8 times greater for those who receive AstraZeneca vaccine.
“There are concerns about possible associations between vaccines and TVC, causing governments and regulators to restrict the use of certain vaccines,” noted Paul Harrison, a professor of psychiatry and head of the Oxford translational neurobiology group. “We have reached two important conclusions. First, COVID-19 significantly increases the risk of CVD, adding to the list of blood clotting problems that cause this infection. Second, the risk of COVID-19 19 is higher than what is seen with current vaccines, even for those under the age of 30, which should be taken into account when considering the balances between the risks and benefits of vaccination. “
Research published by Oxford on Thursday found that about 39 out of every million people who take COVID-19 are likely to experience brain clots. The scientists stressed that their research goal was not to compare vaccines, but to collect firm data on the risks of all vaccines compared to the risks associated with COVID-19 capture.
“The signs that COVID-19 is related to TVC, as well as portal vein thrombosis (a liver clotting disorder), are clear and we need to keep that in mind,” said Dr. Maxime Taquet, a another of the researchers from the Translational Neurobiology Group.
As the figures used to determine overall incidence rates were constantly updated, the researchers stressed that “all comparisons should be interpreted with caution, as data are still accumulating.”
They also noted that it was not yet clear whether “COVID-19 and vaccines lead to TVC by the same or different mechanisms,” and said it would be the subject of their ongoing investigation.